Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT04556032 Terminated - Healthy Clinical Trials

Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women

Start date: September 9, 2020
Phase: N/A
Study type: Interventional

The objective of this study is to assess the effects of ergothioneine at two doses, compared to placebo, on cognition, mood, and sleep in healthy adult men and women.

NCT ID: NCT04540874 Terminated - Healthy Clinical Trials

A Study in Healthy Japanese Men to Test How Different Doses of BI 894416 Are Tolerated

Start date: October 5, 2020
Phase: Phase 1
Study type: Interventional

The objective of this trial is to investigate the safety, tolerability and pharmacokinetics of BI 894416 in healthy Japanese male subjects.

NCT ID: NCT04322227 Terminated - Healthy Clinical Trials

Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects

Start date: January 23, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate effects of foliglurax on brain wave patterns (electric signals) in healthy subjects and in patients with PD

NCT ID: NCT04236453 Terminated - Healthy Clinical Trials

A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents

Start date: January 23, 2020
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the single-dose pharmacokinetics (PK) and pivotal bioequivalence of 3 compounds Darunavir (DRV), emtricitabine (FTC), and tenofovir alafenamide (TAF) in the presence of cobicistat (COBI) when administered as an fixed dose combination (FDC) (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide [D/C/F/TAF]) compared to the co-administration as the separate commercial formulations (DRV and F/TAF and COBI), under fed conditions, in healthy participants.

NCT ID: NCT04230122 Terminated - Healthy Clinical Trials

A Study of LY3478006 in Healthy Participants

Start date: February 17, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to learn more about how safe and how well tolerated LY3478006 is when given by injection into a vein or just under the skin to healthy participants. Blood tests will be done to check how much LY3478006 is in the bloodstream and how long the body takes to get rid of it. For each participant, the study will last up to about 16 weeks, including screening.

NCT ID: NCT04199585 Terminated - Healthy Clinical Trials

Safety and Tolerability of Lu AF95245 in Healthy Young Men

Start date: December 10, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the safety and tolerability of Lu AF95245 and what the body does to Lu AF95245 after swallowing single doses of the drug

NCT ID: NCT04175132 Terminated - Healthy Clinical Trials

Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson's Disease (PD)

Start date: November 12, 2019
Phase: Phase 1
Study type: Interventional

A study to learn how foliglurax binds in regions of the brain

NCT ID: NCT04033458 Terminated - Healthy Clinical Trials

A Study of JNJ-64140284 Solid Dose Formulations in Healthy Male Participants

Start date: July 29, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to compare the pharmacokinetic profile of a single dose of two solid dosage formulations relative to a reference formulation (solution in polyethylene glycol-400 [PEG-400]) of JNJ-64140284 in healthy male participants under fasting condition and to assess the effect of food on the bioavailability of two solid dosage formulations of JNJ-64140284.

NCT ID: NCT04014361 Terminated - Healthy Clinical Trials

A Study of LY3154885 in Healthy Participants

Start date: August 9, 2019
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to learn more about the safety and side effects of LY3154885 when given by mouth to healthy participants. The study will have up to four parts. Each participant will enroll in only one part. The study will last up to 70 days for each participant, including screening and follow-up.

NCT ID: NCT03979820 Terminated - Healthy Clinical Trials

A Study in Healthy People to Test How Combining BI 1467335 and Tyramine Affects Blood Pressure

Start date: July 31, 2019
Phase: Phase 1
Study type: Interventional

The main objective of the study is investigate the effect of escalating doses of oral tyramine on systolic blood pressure (SBP) at baseline and following an oral treatment with BI 1467335 up to 39 days at a low or high dose once daily compared to placebo and phenelzine (Nardil®) as positive control.